The results showed that based on the analysis of age, tumor stage, breast cancer subtype, lymph node metastasis and TP53 mutation, the expression of ITGA3 in breast cancer patients was significantly lower than that in normal controls. This evidence concerns the gene ITGA3 and breast carcinoma.